MDMA (" ecstasy") abuse as an example of dopamine neuroplasticity

Neuroscience and Biobehavioral Reviews

Volumn 35, Issue 5, 2011, Pages 1203-1218

  Schenk, Susan ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Dopamine; Drug abuse; MDMA; Self administration; Sensitization; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; COCAINE; DOPAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; SEROTONIN;

COMPULSION; DEPERSONALIZATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG EXPOSURE; DRUG SEEKING BEHAVIOR; DRUG SENSITIZATION; HUMAN; IN VIVO STUDY; MICRODIALYSIS; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NERVE POTENTIAL; NEUROANATOMY; NEUROCHEMISTRY; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; PERCEPTIVE DISCRIMINATION; PLACE PREFERENCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SENSORY STIMULATION; SEROTONINERGIC TRANSMISSION; SOCIAL BEHAVIOR; WITHDRAWAL SYNDROME;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE; DRUG INTERACTIONS; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONAL PLASTICITY; SELF ADMINISTRATION; SEROTONIN; SUBSTANCE-RELATED DISORDERS;

EID: 79952539171     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2010.12.010     Document Type: Review

References (243)

1. Aberg M., Wade D., Wall E., Izenwasser S. Effect of MDMA (ecstasy) on activity and cocaine conditioned place preference in adult and adolescent rats. Neurotoxicol. Teratol. 2007, 29:37-46.
2. Abreu M.E., Bigelow G.E., Fleisher L., Walsh S.L. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) 2001, 154:76-84.
3. Achat-Mendes C., Anderson K.L., Itzhak Y. Methylphenidate and MDMA adolescent exposure in mice: long-lasting consequences on cocaine-induced reward and psychomotor stimulation in adulthood. Neuropharmacology 2003, 45:106-115.
4. Acquas E., Pisanu A., Spiga S., Plumitallo A., Zernig G., Di Chiara G. Differential effects of intravenous R,S-(+/-)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its S(+)- and R(-)-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell and core. J. Neurochem. 2007, 102:121-132.
5. Aguirre N., Frechilla D., Garcia-Osta A., Lasheras B., Del Rio J. Differential regulation by methylenedioxymethamphetamine of 5-hydroxytryptamine1A receptor density and mRNA expression in rat hippocampus, frontal cortex, and brainstem: the role of corticosteroids. J. Neurochem. 1997, 68:1099-1105.
6. Aguirre N., Galbete J.L., Lasheras B., Del Rio J. Methylenedioxymethamphetamine induces opposite changes in central pre- and postsynaptic 5-HT1A receptors in rats. Eur. J. Pharmacol. 1995, 281:101-105.
7. Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 2007, 113:296-320.
8. Allott K., Redman J. Patterns of use and harm reduction practices of ecstasy users in Australia. Drug Alcohol Depend. 2006, 82:168-176.
9. Appel J.B., West W.B., Rolandi W.G., Alici T., Pechersky K. Increasing the selectivity of drug discrimination procedures. Pharmacol. Biochem. Behav. 1999, 64:353-358.
10. Arborelius L., Nomikos G.G., Hacksell U., Svensson T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand. 1993, 148:465-466.
11. Assie M.B., Ravailhe V., Faucillon V., Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 2005, 315:265-272.
12. Azmitia E.C., Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 1978, 179:641-667.
13. Ball K.T., Budreau D., Rebec G.V. Context-dependent behavioural and neuronal sensitization in striatum to MDMA (ecstasy) administration in rats. Eur. J. Neurosci. 2006, 24:217-228.
14. Ball K.T., Walsh K.M., Rebec G.V. Reinstatement of MDMA (ecstasy) seeking by exposure to discrete drug-conditioned cues. Pharmacol. Biochem. Behav. 2007, 87:420-425.
15. Ball K.T., Wellman C.L., Fortenberry E., Rebec G.V. Sensitizing regimens of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) elicit enduring and differential structural alterations in the brain motive circuit of the rat. Neuroscience 2009, 160:264-274.
16. Banjaw M.Y., Mayerhofer A., Schmidt W.J. Anticataleptic activity of cathinone and MDMA (Ecstasy) upon acute and subchronic administration in rat. Synapse 2003, 49:232-238.
17. Banks M.L., Sprague J.E., Czoty P.W., Nader M.A. Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys. Psychopharmacology (Berl) 2008, 196:63-70.
18. Bankson M.G., Yamamoto B.K. Serotonin-GABA interactions modulate MDMA-induced mesolimbic dopamine release. J. Neurochem. 2004, 91:852-859.
19. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 1988, 149:159-163.
20. Baumann M.H., Clark R.D., Franken F.H., Rutter J.J., Rothman R.B. Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 2008, 152:773-784.
21. Baumann M.H., Clark R.D., Rothman R.B. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol. Biochem. Behav. 2008, 90:208-217.
22. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., Rothman R.B. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 2005, 30:550-560.
23. Baumann M.H., Wang X., Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2007, 189:407-424.
24. Beck J., Rosenbaum M. Pursuit of Ecstasy: The MDMA Experience 1994, State University of New York Press, Albany.
25. Benamar K., Geller E.B., Adler M.W. A new brain area affected by 3,4-methylenedioxymethamphetamine: A microdialysis-biotelemetry study. Eur. J. Pharmacol. 2008, 596(1-3):84-88.
26. Benloucif S., Keegan M.J., Galloway M.P. Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J. Pharmacol. Exp. Ther. 1993, 265:373-377.
27. Bentué-Ferrer D., Reymann J.M., Rousselle J.C., Massot O., Bourin M., Allain H., et al. 5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis. Eur. J. Pharmacol. 1998, 358:129-137.
28. Bevins R.A., Peterson J.L. Individual differences in rats' reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine. Pharmacol. Biochem. Behav. 2004, 79:65-74.
29. Biezonski D.K., Courtemanche A.B., Hong S.B., Piper B.J., Meyer J.S. Repeated adolescent MDMA (Ecstasy) exposure in rats increases behavioral and neuroendocrine responses to a 5-HT2A/2C agonist. Brain Res. 2009, 1252:87-93.
30. Bowers B.J., Henry M.B., Thielen R.J., McBride W.J. Serotonin 5-HT(2) receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat. J. Neurochem. 2000, 75:1625-1633.
31. Brady A.M., Glick S.D., O'Donnell P. Selective disruption of nucleus accumbens gating mechanisms in rats behaviorally sensitized to methamphetamine. J. Neurosci. 2005, 25:6687-6695.
32. Brennan K., Johnstone A., Fitzmaurice P., Lea R., Schenk S. Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA). Drug Alcohol Depend. 2007, 88:204-213.
33. Brennan K.A., Carati C., Lea R.A., Fitzmaurice P.S., Schenk S. Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats. Behav. Pharmacol. 2009, 20:688-694.
34. Brennan K.A., Schenk S. Initial deficit and recovery of function after MDMA preexposure in rats. Psychopharmacology (Berl) 2006, 184:239-246.
35. Broening H.W., Bowyer J.F., Slikker W. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J. Pharmacol. Exp. Ther. 1995, 275:325-333.
36. Bull E.J., Hutson P.H., Fone K.C.F. Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT(2A) receptor responsivity. Neuropharmacology 2004, 46:202-210.
37. Cadoni C., Solinas M., Pisanu A., Zernig G., Acquas E., Di Chiara G. Effect of 3,4-methylendioxymethamphetamine (MDMA, ecstasy) on dopamine transmission in the nucleus accumbens shell and core. Brain Res. 2005, 1055:143-148.
38. Camí J., Farré M., Mas M., Roset P.N., Poudevida S., Mas A., et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (ecstasy): psychomotor performance and subjective effects. J. Clin. Psychopharmacol. 2000, 20:455-466.
39. Camp D.M., Browman K.E., Robinson T.E. The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. Brain Res. 1994, 668:180-193.
40. Capela J.P., Carmo H., Remião F., Bastos M.L., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 2009, 39:210-271.
41. Carlson R.G., Wang J., Falck R.S., Siegal H.A. Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis. Drug Alcohol Depend. 2005, 79:167-179.
42. Carroll M.E., Lac S.T. Acquisition of i.v. amphetamine and cocaine self-administration in rats as a function of dose. Psychopharmacology (Berl) 1997, 129:206-214.
43. Carroll M.E., Lac S.T., Asencio M., Kragh R. Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 1990, 35:237-244.
44. Catlow B.J., Badanich K.A., Sponaugle A.E., Rowe A.R., Song S., Rafalovich I., et al. Effects of MDMA (ecstasy) during adolescence on place conditioning and hippocampal neurogenesis. Eur. J. Pharmacol. 2010, 628:96-103.
45. Chait L.D., Uhlenhuth E.H., Johanson C.E. An experimental paradigm for studying the discriminative stimulus properties of drugs in humans. Psychopharmacology (Berl) 1984, 82:272-274.
46. Chait L.D., Uhlenhuth E.H., Johanson C.E. The discriminative stimulus and subjective effects of d-amphetamine in humans. Psychopharmacology (Berl) 1985, 86:307-312.
47. Chait L.D., Uhlenhuth E.H., Johanson C.E. The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans. Psychopharmacology (Berl) 1986, 89:301-306.
48. Clemens K.J., Cornish J.L., Hunt G.E., McGregor I.S. Intravenous methamphetamine self-administration in rats: effects of intravenous or intraperitoneal MDMA co-administration. Pharmacol. Biochem. Behav. 2006, 85:454-463.
49. Cohen R.S. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995, 19:1137-1145.
50. Cole J.C., Sumnall H.R., O'Shea E., Marsden C.A. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology 2003, 166:383-390.
51. Cole J.C., Sumnall H.R. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci. Biobehav. Rev. 2003, 27:199-217.
52. Colussi-Mas J., Schenk S. Acute and sensitized response to 3,4-methylenedioxymethamphetamine in rats: different behavioral profiles reflected in different patterns of Fos expression. Eur. J. Neurosci. 2008, 28:1895-1910.
53. Colussi-Mas J., Wise R.J., Howard A., Schenk S. Drug seeking in response to a priming injection of MDMA in rats: relationship to initial sensitivity to self-administered MDMA and dorsal striatal dopamine. Int. J. Neuropsychopharmacol. 2010, 1-13.
54. Cottler L.B., Womack S.B., Compton W.M., Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum. Psychopharmacol. 2001, 16:599-606.
55. Czoty P.W., Ginsburg B.C., Howell L.L. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J. Pharmacol. Exp. Ther. 2002, 300:831-837.
56. Dafters R.I. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol. Behav. 1995, 58:877-882.
57. Daniela E., Brennan K., Gittings D., Hely L., Schenk S. Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol. Biochem. Behav. 2004, 77:745-750.
58. Daza-Losada M., Rodríguez-Arias M., Aguilar M.A., Miñarro J. Effect of adolescent exposure to MDMA and cocaine on acquisition and reinstatement of morphine-induce CPP. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:701-709.
59. De Almeida S.P., Silva M.T. Characteristics of ecstasy users in Saio Paulo, Brazil. Subst. Use Misuse 2005, 40:395-404.
60. De La Garza R., Zorick T., London E.D., Newton T.F. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend. 2010, 106:173-180.
61. Degenhardt L., Barker B., Topp L. Patterns of ecstasy use in Australia: findings from a national household survey. Addiction 2004, 99:187-195.
62. Degenhardt L., Bruno R., Topp L. Is ecstasy a drug of dependence?. Drug Alcohol Depend. 2010, 107:1-10.
63. Desai R.I., Paronis C.A., Martin J., Desai R., Bergman J. Monoaminergic psychomotor stimulants: discriminative stimulus effects and dopamine efflux. J. Pharmacol. Exp. Ther. 2010, 333:834-843.
64. Di Chiara G., Bassareo V., Fenu S., De Luca M.A., Spina L., Cadoni C., et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004, 47(Suppl. 1):227-241.
65. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:5274-5278.
66. Di Chiara G., Tanda G., Frau R., Carboni E. On the preferential release of dopamine in the nucleus accumbens by amphetamine: further evidence obtained by vertically implanted concentric dialysis probes. Psychopharmacology (Berl) 1993, 112:398-402.
67. Di Matteo V., Di Giovanni G., Pierucci M., Esposito E. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog. Brain Res. 2008, 172:7-44.
68. Dietz D.M., Dietz K.C., Nestler E.J., Russo S.J. Molecular mechanisms of psychostimulant-induced structural plasticity. Pharmacopsychiatry 2009, 42(Suppl. 1):S69-S78.
69. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J. Psychoactive Drugs 1986, 18:335-340.
70. Dumont G.J., Verkes R.J. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J. Psychopharmacol. 2006, 20:176-187.
71. Esteban B., O'Shea E., Camarero J., Sanchez V., Green A.R., Colado M.I. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 2001, 154:251-260.
72. Evans S.M., Cone E.J., Henningfield J.E. Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J. Pharmacol. Exp. Ther. 1996, 279:1345-1356.
73. Evans S.M., Johanson C.E. Discriminative stimulus properties of (+/-)-3,4-methylenedioxymethamphetamine and (+/-)-3,4-methylenedioxyamphetamine in pigeons. Drug Alcohol Depend. 1986, 18:159-164.
74. Evans S.M., Zacny J.P., Johanson C.E. Three-choice discrimination among (+)-amphetamine, fenfluramine and saline in pigeons. Pharmacol. Biochem. Behav. 1990, 35:971-980.
75. Falk E.M., Cook V.J., Nichols D.E., Sprague J.E. An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol. Biochem. Behav. 2002, 72:617-622.
76. Farré M., de la Torre R., Mathúna B.O., Roset P.N., Peiró A.M., Torrens M., et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 2004, 173:364-375.
77. Fischman M.W., Schuster C.R., Javaid J., Hatano Y., Davis J. Acute tolerance development to the cardiovascular and subjective effects of cocaine. J. Pharmacol. Exp. Ther. 1985, 235:677-682.
78. Fletcher P.J., Robinson S.R., Slippoy D.L. Pre-exposure to (+/-)3,4-methylenedioxy-methamphetamine (MDMA) facilitates acquisition of intravenous cocaine self-administration in rats. Neuropsychopharmacology 2001, 25:195-203.
79. Foltin R.W., Fischman M.W. Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J. Pharmacol. Exp. Ther. 1991, 257:247-261.
80. Fone K.C., Beckett S.R., Topham I.A., Swettenham J., Ball M., Maddocks L. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl) 2002, 159:437-444.
81. Fox H.C., Parrott A.C., Turner J.J. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J. Psychopharmacol. 2001, 15:273-281.
82. Frederick D.L., Ali S.F., Gillam M.P., Gossett J., Slikker W., Paule M.G. Acute effects of dexfenfluramine (d-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment. Ann. N. Y. Acad. Sci. 1998, 844:183-190.
83. Freedman R.R., Johanson C.E., Tancer M.E. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2005, 183:248-256.
84. Galloway M.P., Suchowski C.S., Keegan M.J., Hjorth S. Local infusion of the selective 5HT-1b agonist CP-93,129 facilitates striatal dopamine release in vivo. Synapse 1993, 15:90-92.
85. Gartside S.E., McQuade R., Sharp T. Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo. J. Pharmacol. Exp. Ther. 1996, 279:277-283.
86. Gauvin D.V., Harland R.D., Holloway F.A. Drug discrimination procedures: a method to analyze adaptation level of affective states. Drug Dev. Res. 1989, 16:183-194.
87. George J., Kinner S.A., Bruno R., Degenhardt L., Dunn M. Contextualising psychological distress among regular ecstasy users: the importance of sociodemographic factors and patterns of drug use. Drug Alcohol Rev. 2010, 29:243-249.
88. Giannaccini G., Betti L., Pirone A., Palego L., Fabiani O., Fabbrini L., et al. Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus. Neurochem. Int. 2007, 51:496-506.
89. Glennon R.A., Higgs R., Young R., Issa H. Further studies on N-methyl-1(3,4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus: antagonism by 5-hydroxytryptamine3 antagonists. Pharmacol. Biochem. Behav. 1992, 43:1099-1106.
90. Glennon R.A., Misenheimer B.R. Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline. Pharmacol. Biochem. Behav. 1989, 33:909-912.
91. Gobert A., Rivet J.M., Audinot V., Newman-Tancredi A., Cistarelli L., Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 1998, 84:413-429.
92. Goodwin A.K., Baker L.E. A three-choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and (+/-)-MDMA in rats. Exp. Clin. Psychopharmacol. 2000, 8:415-423.
93. Goodwin A.K., Pynnonen D.M., Baker L.E. Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination. Pharmacol. Biochem. Behav. 2003, 74:987-995.
94. Götestam K.G., Andersson B.E. Self-administration of amphetamine analogues in rats. Pharmacol. Biochem. Behav. 1975, 3:229-233.
95. Gouzoulis-Mayfrank E., Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J. Psychopharmacol. 2006, 20:188-193.
96. Granoff M.I., Ashby C.R. Effect of the repeated administration of (+/-)-3,4-methylenedioxymethamphetamine on the behavioral response of rats to the 5-HT1A receptor agonist (+/-)-8-hydroxy-(di-n-propylamino)tetralin. Neuropsychobiology 2001, 43:42-48.
97. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology (Berl) 1995, 119:247-260.
98. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol. Rev. 2003, 55:463-508.
99. Greer G., Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J. Psychoactive Drugs 1986, 18:319-327.
100. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 1996, 66:243-249.
101. Gudelsky G.A., Yamamoto B.K. Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine. Methods Mol. Med. 2003, 79:55-73.
102. Haertzen C.A., Hill H.E. Assessing subjective effects of drugs: an index of carelessness and confusion for use with the Addiction Research Center Inventory (ARCI). J. Clin. Psychol. 1963, 19:407-412.
103. Hamida S.B., Plute E., Cosquer B., Kelche C., Jones B.C., Cassel J.C. Interactions between ethanol and cocaine, amphetamine, or MDMA in the rat: thermoregulatory and locomotor effects. Psychopharmacology (Berl) 2008, 197:67-82.
104. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2002, 162:396-405.
105. Hart C.L., Gunderson E.W., Perez A., Kirkpatrick M.G., Thurmond A., Comer S.D., et al. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 2008, 33:1847-1855.
106. Hasler F., Studerus E., Lindner K., Ludewig S., Vollenweider F.X. Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J. Psychopharmacol. 2009, 23:923-935.
107. Hernández-López C., Farré M., Roset P.N., Menoyo E., Pizarro N., Ortuño J., et al. 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J. Pharmacol. Exp. Ther. 2002, 300:236-244.
108. Hooks M.S., Jones G.H., Neill D.B., Justice J.B. Individual differences in amphetamine sensitization: dose-dependent effects. Pharmacol. Biochem. Behav. 1992, 41:203-210.
109. Horan B., Gardner E.L., Ashby C.R. Enhancement of conditioned place preference response to cocaine in rats following subchronic administration of 3,4-methylenedioxymethamphetamine (MDMA). Synapse 2000, 35:160-162.
110. Horger B.A., Shelton K., Schenk S. Preexposure sensitizes rats to the rewarding effects of cocaine. Pharmacol. Biochem. Behav. 1990, 37:707-711.
111. Howell L.L., Byrd L.D. Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J. Pharmacol. Exp. Ther. 1995, 275:1551-1559.
112. Hubner C.B., Bird M., Rassnick S., Kornetsky C. The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward. Psychopharmacology (Berl) 1988, 95:49-51.
113. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001, 76:1521-1531.
114. Javaid J.I., Fischman M.W., Schuster C.R., Dekirmenjian H., Davis J.M. Cocaine plasma concentration: relation to physiological and subjective effects in humans. Science 1978, 202:227-228.
115. Jayaram-Lindström N., Konstenius M., Eksborg S., Beck O., Hammarberg A., Franck J. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 2008, 33:1856-1863.
116. Johanson C.E., Kilbey M., Gatchalian K., Tancer M. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend. 2006, 81:27-36.
117. Jones K., Brennan K.A., Colussi-Mas J., Schenk S. Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release. Addict. Biol. 2010, 15:289-298.
118. Kalivas P.W. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 2009, 10:561-572.
119. Kalivas P.W., Duffy P., White S.R. MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 1998, 18:469-479.
120. Kalivas P.W., Sorg B.A., Hooks M.S. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav. Pharmacol. 1993, 4:315-334.
121. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug and stress-induced sensitization of motor activity. Brain Res. Brain Res. Rev. 1991, 16:223-244.
122. Kamien J.B., Johanson C.E., Schuster C.R., Woolverton W.L. The effects of (+/-)-methylenedioxymethamphetamine and (+/-)-methylenedioxyamphetamine in monkeys trained to discriminate (+)-amphetamine from saline. Drug Alcohol Depend. 1986, 18:139-147.
123. Kankaanpää A., Meririnne E., Lillsunde P., Seppälä T. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol. Biochem. Behav. 1998, 59:1003-1009.
124. Keyes K.M., Martins S.S., Hasin D.S. Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on alcohol and related conditions. Drug Alcohol Depend. 2008, 97:139-149.
125. Kimmel H.L., Manvich D.F., Blough B.E., Negus S.S., Howell L.L. Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacol. Biochem. Behav. 2009, 94:278-284.
126. Kindlundh-Högberg A.M., Blomqvist A., Malki R., Schiöth H.B. Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats. BMC Neurosci. 2008, 9:39.
127. Kindlundh-Högberg A.M., Svenningsson P., Schiöth H.B. Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain. Neuropharmacology 2006, 51:838-847.
128. Koch S., Galloway M.P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural Transm. 1997, 104:135-146.
129. Kolbrich E.A., Goodwin R.S., Gorelick D.A., Hayes R.J., Stein E.A., Huestis M.A. Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J. Clin. Psychopharmacol. 2008, 28:432-440.
130. Kollins S.H., Rush C.R. Effects of training dose on the relationship between discriminative-stimulus and self-reported drug effects of d-amphetamine in humans. Pharmacol. Biochem. Behav. 1999, 64:319-326.
131. Kosten T., Silverman D.G., Fleming J., Kosten T.A., Gawin F.H., Compton M., et al. Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol. Psychiatry 1992, 32:543-548.
132. Kueh D., Baker L.E. Reinforcement schedule effects in rats trained to discriminate 3,4-methylenedioxymethamphetamine (MDMA) or cocaine. Psychopharmacology (Berl) 2007, 189:447-457.
133. Kurling S., Kankaanpää A., Seppälä T. Sub-chronic nandrolone treatment modifies neurochemical and behavioral effects of amphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in rats. Behav. Brain Res. 2008, 189:191-201.
134. Lamb R.J., Henningfield J.E. Human d-amphetamine drug discrimination: methamphetamine and hydromorphone. J. Exp. Anal. Behav. 1994, 61:169-180.
135. Leccese A.P., Lyness W.H. The effects of putative 5-hydroxytryptamine receptor active agents on d-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions. Brain Res. 1984, 303:153-162.
136. Leung K.S., Ben Abdallah A., Copeland J., Cottler L.B. Modifiable risk factors of ecstasy use: risk perception, current dependence, perceived control, and depression. Addict. Behav. 2010, 35:201-208.
137. Liechti M.E., Baumann C., Gamma A., Vollenweider F.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000, 22:513-521.
138. Liechti M.E., Saur M.R., Gamma A., Hell D., Vollenweider F.X. Psychological and physiological effects of MDMA (Ecstasy) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000, 23:396-404.
139. Liechti M.E., Gamma A., Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 2001, 154:161-168.
140. Liechti M.E., Vollenweider F.X. Acute psychological and physiological effects of MDMA (Ecstasy) after haloperidol pretreatment in healthy humans. Eur. Neuropsychopharmacol. 2000, 10:289-295.
141. Liechti M.E., Vollenweider F.X. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J. Psychopharmacol. 2000, 14:269-274.
142. Lile J.A., Ross J.T., Nader M.A. A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) with cocaine in rhesus monkeys. Drug Alcohol Depend. 2005, 78:135-140.
143. Lin S.K., Pan W.H., Yeh P.H. Prefrontal dopamine efflux during exposure to drug-associated contextual cues in rats with prior repeated methamphetamine. Brain Res. Bull. 2007, 71:365-371.
144. Lott D.C., Kim S.J., Cook E.H., de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005, 30:602-609.
145. Ludwig V., Mihov Y., Schwarting R.K. Behavioral and neurochemical consequences of multiple MDMA administrations in the rat: role of individual differences in anxiety-related behavior. Behav. Brain Res. 2008, 189:52-64.
146. Marona-Lewicka D., Rhee G.S., Sprague J.E., Nichols D.E. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol. Biochem. Behav. 1996, 53:99-105.
147. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 1971, 12:245-258.
148. Matthews R.T., Champney T.H., Frye G.D. Effects of (+-)3,4-methylenedioxymethamphetamine (MDMA) on brain dopaminergic activity in rats. Pharmacol. Biochem. Behav. 1989, 33:741-747.
149. Mayerhofer A., Kovar K.A., Schmidt W.J. Changes in serotonin, dopamine and noradrenaline levels in striatum and nucleus accumbens after repeated administration of the abused drug MDMA in rats. Neurosci. Lett. 2001, 308:99-102.
150. McClung J., Fantegrossi W., Howell L.L. Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. Psychopharmacology (Berl) 2010, 210:75-83.
151. McGregor I.S., Clemens K.J., Van der Plasse G., Li K.M., Hunt G.E., Chen F., et al. Increased anxiety 3 months after brief exposure to MDMA (Ecstasy) in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 2003, 28:1472-1484.
152. Mechan A.O., Esteban B., O'Shea E., Elliott J.M., Colado M.I., Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol. 2002, 135:170-180.
153. Mello N.K., Mendelson J.H., Sholar M.B., Jaszyna-Gasior M., Goletiani N., Siegel A.J. Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology 2005, 30:618-632.
154. Modi G.M., Yang P.B., Swann A.C., Dafny N. Chronic exposure to MDMA (ecstasy) elicits behavioral sensitization in rats but fails to induce cross-sensitization to other psychostimulants. Behav. Brain Funct. 2006, 2:1-29.
155. Morgan A.E., Horan B., Dewey S.L., Ashby C.R. Repeated administration of 3,4-methylenedioxymethamphetamine augments cocaine's action on dopamine in the nucleus accumbens: a microdialysis study. Eur. J. Pharmacol. 1997, 331:R1-R3.
156. Morley K.C., Cornish J.L., Li K.M., McGregor I.S. Preexposure to MDMA (Ecstasy) delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats. Pharmacol. Biochem. Behav. 2004, 79:331-342.
157. Munzar P., Baumann M.H., Shoaib M., Goldberg S.R. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. Psychopharmacology (Berl) 1999, 141:287-296.
158. Nair S.G., Gudelsky G.A. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat. Brain Res. 2004, 1013:168-173.
159. Negus S.S., Mello N.K., Blough B.E., Baumann M.H., Rothman R.B. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate agonist medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 320:627-636.
160. Newton T.F., Roache J.D., De La Garza R., Fong T., Wallace C.L., Li S.H., et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006, 31:1537-1544.
161. Nichols D.E., Oberlender R. Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs?. Ann. N. Y. Acad. Sci. 1990, 600:613-623. discussion 623-615.
162. Nielsen E.B., Scheel-Kruger J. Central nervous system stimulants: neuropharmacological mechanisms. Psychopharmacol. Ser. 1988, 4:57-72.
163. Oberlender R., Nichols D.E. Drug discrimination studies with MDMA and amphetamine. Psychopharmacology (Berl) 1988, 95:71-76.
164. O'Dell L.E., Parsons L.H. Serotonin1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J. Pharmacol. Exp. Ther. 2004, 311:711-719.
165. O'Shea E., Escobedo I., Orio L., Sanchez V., Navarro M., Green A.R., et al. Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology 2005, 30:1312-1323.
166. Oslin D.W., Pettinati H.M., Volpicelli J.R., Wolf A.L., Kampman K.M., O'Brien C.P. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J. Subst. Abuse Treat. 1999, 16:163-167.
167. Oswald L.M., Wong D.F., McCaul M., Zhou Y., Kuwabara H., Choi L., et al. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 2005, 30:821-832.
168. Panos J.J., Baker L.E. An in vivo microdialysis assessment of concurrent MDMA and cocaine administration in Sprague-Dawley rats. Psychopharmacology (Berl) 2010, 209:95-102.
169. Parrott A.C. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum. Psychopharmacol. 2001, 16:557-577.
170. Parrott A.C. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. J. Psychopharmacol. 2005, 19:71-83.
171. Pehek E.A., McFarlane H.G., Maguschak K., Price B., Pluto C.P. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res. 2001, 888:51-59.
172. Pehek E.A., Nocjar C., Roth B.L., Byrd T.A., Mabrouk O.S. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 2006, 31:265-277.
173. Peltier R., Schenk S. Effects of serotonergic manipulations on cocaine self-administration in rats. Psychopharmacology (Berl) 1993, 110:390-394.
174. Peroutka S.J., Newman H., Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988, 1:273-277.
175. Peterson A.L., Gilman T.L., Banks M.L., Sprague J.E. Hypothyroidism alters striatal dopamine release mediated by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Synapse 2006, 59:317-319.
176. Piazza P.V., Deminiere J.M., le Moal M., Simon H. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res. 1990, 514:22-26.
177. Pierce R.C., Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Brain Res. Rev. 1997, 25:192-216.
178. Pierce R.C., Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci. Biobehav. Rev. 2006, 30:215-238.
179. Piper B.J., Fraiman J.B., Meyer J.S. Repeated MDMA (Ecstasy) exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding. Dev. Psychobiol. 2005, 47:145-157.
180. Piper B.J., Meyer J.S. Increased responsiveness to MDMA in adult rats treated neonatally with MDMA. Neurotoxicol. Teratol. 2006, 28:95-102.
181. Porrino L.J., Ritz M.C., Goodman N.L., Sharpe L.G., Kuhar M.J., Goldberg S.R. Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats. Life Sci. 1989, 45:1529-1535.
182. Ramos M., Goñi-Allo B., Aguirre N. Studies on the role of dopamine D1 receptors in the development and expression of MDMA-induced behavioral sensitization in rats. Psychopharmacology (Berl) 2004, 177:100-110.
183. Ramos M., Goñi-Allo B., Aguirre N. Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: an effect mediated by 5-HT(2C) receptor stimulation and not by D(1) receptor blockade. Neuropsychopharmacology 2005.
184. Ramos M., Goñi-Allo B., Aguirre N. Ibotenic acid lesions of the medial prefrontal cortex block the development and expression of 3,4-methylenedioxymethamphetamine-induced behavioral sensitization in rats. Behav. Brain Res. 2005, 160:304-311.
185. Rasmusson A.M., Goldstein L.E., Deutch A.Y., Bunney B.S., Roth R.H. 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 1994, 18:218-224.
186. Ren J., Xu H., Choi J.K., Jenkins B.G., Chen Y.I. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses. Synapse 2009, 63:764-772.
187. Reveron M.E., Maier E.Y., Duvauchelle C.L. Behavioral, thermal and neurochemical effects of acute and chronic 3,4-methylenedioxymethamphetamine (Ecstasy) self-administration. Behav. Brain Res. 2010, 207:500-507.
188. Richardson N.R., Roberts D.C. Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci. 1991, 49:833-840.
189. Ritz M.C., Kuhar M.J. Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J. Pharmacol. Exp. Ther. 1989, 248:1010-1017.
190. Roberts D.C., Phelan R., Hodges L.M., Hodges M.M., Bennett B., Childers S., et al. Self-administration of cocaine analogs by rats. Psychopharmacology (Berl) 1999, 144:389-397.
191. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 1986, 396:157-198.
192. Robinson T.E., Jurson P.A., Bennett J.A., Bentgen K.M. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res. 1988, 462:211-222.
193. Robinson T.E., Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 2004, 47:33-46.
194. Rodgers J., Buchanan T., Scholey A.B., Heffernan T.M., Ling J., Parrott A.C. Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web-based study. J. Psychopharmacol. 2003, 17:389-396.
195. Rollema H., Lu Y., Schmidt A.W., Sprouse J.S., Zorn S.H. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry 2000, 48:229-237.
196. Rush C.R., Stoops W.W., Hays L.R., Glaser P.E., Hays L.S. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J. Pharmacol. Exp. Ther. 2003, 306:195-204.
197. Rush C.R., Stoops W.W., Wagner F.P., Hays L.R., Glaser P.E. Alprazolam attenuates the behavioral effects of d-amphetamine in humans. J. Clin. Psychopharmacol. 2004, 24:410-420.
198. Schechter M.D. Discriminative profile of MDMA. Pharmacol. Biochem. Behav. 1986, 24:1533-1537.
199. Schechter M.D. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol. Biochem. Behav. 1988, 31:817-824.
200. Schechter M.D. Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination. Pharmacol. Biochem. Behav. 1991, 38:539-544.
201. Schechter M.D. MDMA-like stimulus effects of hallucinogens in male Fawn-Hooded rats. Pharmacol. Biochem. Behav. 1998, 59:265-270.
202. Scheffel U., Lever J.R., Stathis M., Ricaurte G.A. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology 1992, 31:881-893.
203. Schenk S. MDMA self-administration in laboratory animals: a summary of the literature and proposal for future research. Neuropsychobiology 2009, 60:130-136.
204. Schenk S., Gittings D., Johnstone M., Daniela E. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 2003, 169:21-27.
205. Schenk S., Hely L., Gittings D., Lake B., Daniela E. Effects of priming injections of MDMA and cocaine on reinstatement of MDMA- and cocaine-seeking in rats. Drug Alcohol Depend. 2008, 96:249-255.
206. Schenk S., Hely L., Lake B., Daniela E., Gittings D., Mash D.C. MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur. J. Neurosci. 2007, 26:3229-3236.
207. Schenk S., Valadez A., McNamara C., House D.T., Higley D., Bankson M.G., et al. Development and expression of sensitization to cocaine's reinforcing properties: role of NMDA receptors. Psychopharmacology (Berl) 1993, 111:332-338.
208. Schenk, S., Gittings, D., Colusi-Mas, J. Dopaminergic mechanisms of reinstatement of MDMA-seeking behaviour in rats. Br. J. Pharmacol., in press.
209. Schmidt C.J., Levin J.A., Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol. 1987, 36:747-755.
210. Schmidt C.J., Sullivan C.K., Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 1994, 62:1382-1389.
211. Schmitz J.M., Stotts A.L., Rhoades H.M., Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict. Behav. 2001, 26:167-180.
212. Scholey A.B., Parrott A.C., Buchanan T., Heffernan T.M., Ling J., Rodgers J. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict. Behav. 2004, 29:743-752.
213. Shankaran M., Gudelsky G.A. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl) 1999, 147:66-72.
214. Shoblock J.R., Sullivan E.B., Maisonneuve I.M., Glick S.D. Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology (Berl) 2003, 165:359-369.
215. Shutoh F., Hamada S., Shibata M., Narita M., Shiga T., Azmitia E.C., et al. Long term depletion of serotonin leads to selective changes in glutamate receptor subunits. Neurosci. Res. 2000, 38:365-371.
216. Skelton M.R., Williams M.T., Vorhees C.V. Developmental effects of 3,4-methylenedioxymethamphetamine: a review. Behav. Pharmacol. 2008, 19:91-111.
217. Smith F.L., Yu D.S., Smith D.G., Leccese A.P., Lyness W.H. Dietary tryptophan supplements attenuate amphetamine self-administration in the rat. Pharmacol. Biochem. Behav. 1986, 25:849-855.
218. Soar K., Turner J.J., Parrott A.C. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. J. Psychopharmacol. 2006, 20:417-424.
219. Solowij N., Hall W., Lee N. Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug. Br. J. Addict. 1992, 87:1161-1172.
220. Spanos L.J., Yamamoto B.K. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol. Biochem. Behav. 1989, 32:835-840.
221. Stove C.P., De Letter E.A., Piette M.H., Lambert W.E. Mice in ecstasy: advanced animal models in the study of MDMA. Curr. Pharm. Biotechnol. 2010, 11:421-433.
222. Tancer M., Johanson C.E. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend. 2003, 72:33-44.
223. Tancer M., Johanson C.E. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2007, 189:565-573.
224. Tancer M.E., Johanson C.E. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 2001, 65:97-101.
225. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?. Psychopharmacology (Berl) 1994, 115:285-288.
226. Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend. 1999, 55:105-115.
227. Yan Q.S., Zheng S.Z., Yan S.E. Involvement of 5-HT1B receptors within the ventral tegmental area in regulation of mesolimbic dopaminergic neuronal activity via GABA mechanisms: a study with dual-probe microdialysis. Brain Res. 2004, 1021:82-91.
228. Vanderschuren L.J., Schoffelmeer A.N., Mulder A.H., De Vries T.J. Lack of cross-sensitization of the locomotor effects of morphine in amphetamine-treated rats. Neuropsychopharmacology 1999, 21:550-559.
229. Vansickel A.R., Lile J.A., Stoops W.W., Rush C.R. Similar discriminative-stimulus effects of d-amphetamine in women and men. Pharmacol. Biochem. Behav. 2007, 87:289-296.
230. Vezina P. Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci. Biobehav. Rev. 2004, 27:827-839.
231. Volkow N.D., Fowler J.S., Wang G.J. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav. Pharmacol. 2002, 13:355-366.
232. Vollenweider F.X., Gamma A., Liechti M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (ecstasy) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998, 19:241-251.
233. Vollenweider F.X., Liechti M.E., Gamma A., Greer G., Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. J. Psychoactive Drugs 2002, 34:171-184.
234. von Sydow K., Lieb R., Pfister H., Hofler M., Wittchen H.U. Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults - a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend. 2002, 66:147-159.
235. Wang Z., Woolverton W.L. Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology (Berl) 2007, 189:483-488.
236. Wee S., Anderson K.G., Baumann M.H., Rothman R.B., Blough B.E., Woolverton W.L. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J. Pharmacol. Exp. Ther. 2005, 313:848-854.
237. Wee S., Woolverton W.L. Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacol. Biochem. Behav. 2006, 84:337-343.
238. White S.R., Obradovic T., Imel K.M., Wheaton M.J. The effects of methylenedioxymethamphetamine (MDMA, Ecstasy) on monoaminergic neurotransmission in the central nervous system. Prog. Neurobiol. 1996, 49:455-479.
239. White T.L., Lott D.C., de Wit H. Personality and the subjective effects of acute amphetamine in healthy volunteers. Neuropsychopharmacology 2006, 31:1064-1074.
240. Wu L.T., Parrott A.C., Ringwalt C.L., Yang C., Blazer D.G. The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions. Am. J. Addict. 2009, 18:452-461.
241. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 1995, 273:1063-1070.
242. Yan Q.S., Yan S.E. Activation of 5-HT(1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur. J. Pharmacol. 2001, 418:55-64.
243. Zacny J.P., Virus R.M., Woolverton W.L. Tolerance and cross-tolerance to 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine. Pharmacol. Biochem. Behav. 1990, 35:637-642.